News

May 22, 2013: Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
May 14, 2013: Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch Health Care Conference
May 10, 2013: Oncolytics Biotech® Inc. Announces Director Election Results from its Annual and Special Meeting of Shareholders
May 09, 2013: Oncolytics Biotech® Inc. Announces First Quarter 2013 Results
May 06, 2013: Oncolytics Biotech® Inc. Announces Details of 2013 Annual and Special Meeting of Shareholders
April 29, 2013: Media Advisory - Oncolytics Biotech® Inc. to Present at 12th Annual Needham Healthcare Conference
March 28, 2013: Oncolytics Biotech® Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer
March 14, 2013: Oncolytics Biotech® Inc. Announces 2012 Year End Results
March 05, 2013: Oncolytics Biotech® Inc. Completes Patient Enrollment in U.S. Phase 2 Study of REOLYSIN® in Non-Small Cell Lung Cancer
February 25, 2013: Media Advisory - Oncolytics Biotech® Inc. to Present at RBC Capital Markets 2013 Healthcare Conference
February 25, 2013: Oncolytics Biotech® Inc. Announces Closing of Common Share Offering
February 20, 2013: Oncolytics Biotech® Inc. Announces Addition to Senior Management Team
February 20, 2013: Oncolytics Biotech® Inc. Announces Pricing of Common Share Offering
February 19, 2013: Oncolytics Biotech® Inc. Announces Common Share Offering
February 08, 2013: Oncolytics Biotech® Inc. Announces Additional Positive REOLYSIN® Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung
January 28, 2013: Oncolytics Biotech® Inc. Announces Positive REOLYSIN® Clinical Trial Data Presented at ASCO Gastrointestinal Cancers Symposium
December 13, 2012: Oncolytics Biotech Inc. Announces Positive Top Line REOLYSIN® Data for First Endpoint in Randomized Phase III Study in Head and Neck Cancers

Search News

Latest News